Nu Skin Enterprises, Inc.
NUS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -1.22 | -0.71 | -0.87 |
| FCF Yield | 20.50% | 6.23% | 2.32% | 2.86% |
| EV / EBITDA | -8.04 | 6.49 | 10.20 | 7.36 |
| Quality | ||||
| ROIC | -10.40% | 1.02% | 8.61% | 9.77% |
| Gross Margin | 68.23% | 68.93% | 72.86% | 74.95% |
| Cash Conversion Ratio | -0.76 | 13.80 | 1.03 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | -8.02% | -9.94% | -4.83% | 3.66% |
| Free Cash Flow Growth | 16.64% | 22.74% | -32.84% | -76.86% |
| Safety | ||||
| Net Debt / EBITDA | -3.70 | 1.73 | 1.10 | 0.45 |
| Interest Coverage | -5.74 | 1.89 | 5.07 | 21.27 |
| Efficiency | ||||
| Inventory Turnover | 2.89 | 2.19 | 1.82 | 1.69 |
| Cash Conversion Cycle | 113.76 | 154.58 | 176.82 | 194.76 |